Jeffrey J. Legos, Ph.D.
Affiliations: | 2000 | Temple University, Philadelphia, PA, United States |
Area:
Neuroscience Biology, Pharmacology, Cell Biology, Molecular BiologyGoogle:
"Jeffrey Legos"Parents
Sign in to add mentor| Ronald Tuma | grad student | 2000 | Temple University | |
| (The role of p38 MAP kinase cell signaling pathways in focal stroke.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Long GV, Hauschild A, Santinami M, et al. (2017) Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. The New England Journal of Medicine |
| Schadendorf D, Long GV, Stroiakovski D, et al. (2017) Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European Journal of Cancer (Oxford, England : 1990). 82: 45-55 |
| Long GV, Stroyakovskiy D, Gogas H, et al. (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England). 386: 444-51 |
| Hauschild A, Grobb J, Demidov L, et al. (2014) 1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv378 |
| Robert C, Karaszewska B, Schachter J, et al. (2014) Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma Annals of Oncology. 25: v1 |
| Legos JJ, Lenhard SC, Haimbach RE, et al. (2008) SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Experimental Neurology. 212: 53-62 |
| McLaughlin B, Hartnett KA, Erhardt JA, et al. (2003) Caspase 3 activation is essential for neuroprotection in preconditioning. Proceedings of the National Academy of Sciences of the United States of America. 100: 715-20 |
| Legos JJ, McLaughlin B, Skaper SD, et al. (2002) The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. European Journal of Pharmacology. 447: 37-42 |
| Legos JJ, Tuma RF, Barone FC. (2002) Pharmacological interventions for stroke: failures and future. Expert Opinion On Investigational Drugs. 11: 603-14 |
| Weaver M, Leshley K, Sands H, et al. (2002) LEX032, a novel recombinant serpin, protects the brain after transient focal ischemia. Microvascular Research. 63: 327-34 |